- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659109
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 (GARDEN)
A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
This randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study evaluates the efficacy and safety of glenzocimab in ARDS.
Patients will be screened for eligibility and all tests should have results prior to any randomization, so as to avoid screening failures to a maximum extent. The turn-around time for these tests should be comprised within 24hrs to allow for rapid inclusions if needed. Eligible patients (n=68) will be randomized in a 1:1 ratio to glenzocimab or placebo. Patient inclusions will be fractioned into sequential (3-day apart) cohorts of growing size (2, 4 then 6 patients), each balanced between glenzocimab and placebo in order to check safety in a gradual manner. A Data Safety Monitoring Board (DSMB) will meet after 12 patients will have been accrued, and again after the first 30 patients.
Glenzocimab will be administered by IV infusion. The dosing regimen will be 1000mg for 3 days. All patients will receive in parallel the best medical care at the discretion of the investigating center, or per local guidelines. The allocation of each patient in any given center to an active treatment or placebo will strictly follow a central randomization scheme. The study period will be of a maximum of 40 days per patient. Patients will be closely monitored during the first 7 days following randomization with complete evaluations being performed at 24 hrs, 48 hrs, 72 hrs, then on Days 4 (96 hrs), 5 (120 hrs), 7 (+/-1 day), 14 (+/-2 days), 20 (+/-2 days), 40 (+/-3 days). Should a patient being discharged before Day 40, distant consultations by telemedicine may be undertaken if it is not deemed desirable that the patient comes back to the institution.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67091
- Hopital de Hautepierre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female hospitalized patients ≥ 18 years (i.e., at least 18 years old at the time of randomization), having given their written consent.
- Having a positive RT-PCR test for COVID-19
Presenting with symptoms of COVID-19, including:
- Cough OR
- Shortness of breath or difficulty breathing OR at least 2 of the following
- Fever, defined as any body temperature 38°C
- Chills
- Repeated shaking with chills
- Muscle pain
- Headache
- Sore throat
- New loss of taste or smell
Presenting with signs of moderate but progressive pulmonary disease with:
- respiratory symptoms (cough, dyspnea, etc.),
- uni- or bilateral ground-glass opacities, or pulmonary infiltrates on chest radiograph and/or CT scan,
- clinical and biological evidence of progression over the past 48hrs.
Effective birth control that should have been in place for at least 2 months in non-menopausal women and 4 months for men after IMP administration. Birth control methods considered to be highly effective include:
- combined (estrogen-progestogen) hormonal contraception associated with the inhibition of ovulation: oral, intravaginal, transdermal,
- progesterone-only hormonal contraception associated with the inhibition of ovulation: oral, injectable, implantable,
- intrauterine device,
- intrauterine hormone-releasing system,
- bilateral tubal occlusion,
- vasectomized partner.
- Women of child-bearing potential must have negative results of a urinary or plasma pregnancy test (serum HCG).
Exclusion Criteria:
- Patients requiring immediate admission to the ICU,
- Patients requiring invasive mechanical ventilation,
- ARDS of another origin,
- Concomitant pulmonary infection (pneumoniae) with another agent, notably bacterial or fungal,
- Patients under immunosuppressive agents,
- Childbirth within <10 days,
- Pregnancy or breastfeeding,
- Prior cardiopulmonary resuscitation <10 days,
- Allergy or hypersensitivity to drugs of the same class
- Participation in another interventional clinical trial within 30 days prior to the inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
IV administration
|
Experimental: glenzocimab 1000 mg
|
IV administration as a sterile product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression from moderate to severe respiratory distress assessed at Day 4
Time Frame: Day 4
|
Progression from moderate to severe assessed at Day 4 is a composite failure endpoint defined as the occurrence of at least one of the following failure events :
|
Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality at day 40
Time Frame: Day 40 (maximum)
|
Day 40 (maximum)
|
|
WHO-COVID-19 Scale
Time Frame: Up to Day 40
|
WHO COVID-19 Ordinal Scoring Scale is 9 point ordinal scale
|
Up to Day 40
|
NEWS-2 Scale
Time Frame: Up to Day 40
|
Determines the degree of illness of a patient and prompts critical care intervention (recommended by NHS over original NEWS): total possible score ranges from 0 to 20.
The higher the scores the greater the clinical risk.
|
Up to Day 40
|
Respiratory Rate status (RR)
Time Frame: Up to Day 40
|
Respiratory Rate status defined as:: o Normal:<20/min,
|
Up to Day 40
|
Hypoxemia status
Time Frame: Up to Day 40
|
Hypoxemia status defined as:: o Normal:>300mmHg,
|
Up to Day 40
|
SpO2 status
Time Frame: Up to Day 40
|
SpO2 status defined as: o Normal:>95%
|
Up to Day 40
|
CHEST CT-Scan (or in exceptional cases, chest radiogram)
Time Frame: Day 4
|
Day 4
|
|
Oxygen-free days
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Admission to the ICU
Time Frame: Up to Day 40
|
Up to Day 40
|
|
ICU-free days
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Hospital-free days
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Clinical recovery and Time to Clinical recovery
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Cure and Time-to-cure
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Incidence, nature and severity of Adverse Events, SAEs, SUSARs and Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Incidence of bleeding-related events
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Incidence of hypersensitivity reactions
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on blood pressure
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on heart rate
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on NFS
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on INR/PTT
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on platelet count
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on plasma fibrinogen level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on plasma D-Dimers level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on serum-glucose level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on urea level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on creatinemia
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on LFTs (ASAT/ALAT)
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on CRP level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on LDH level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on IL6 level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on Tnt
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on NT proBNP
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on procalcitonin level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
Changes from baseline on ferritin level
Time Frame: Up to Day 40
|
Up to Day 40
|
|
ECG over the course of the study versus screening
Time Frame: Up to Day 40
|
Changes in one or several of the usual ECG parameters compared to baseline or screening, i.e. sinusal rhythm, cardiac axis, QRS value, QT/QTc segment, Wave direction, and any abnormality.
|
Up to Day 40
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Renaud L, Lebozec K, Voors-Pette C, Dogterom P, Billiald P, Jandrot Perrus M, Pletan Y, Machacek M. Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation. J Clin Pharmacol. 2020 Sep;60(9):1198-1208. doi: 10.1002/jcph.1616. Epub 2020 Jun 4.
- Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, Pletan Y, Jandrot-Perrus M. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. doi: 10.1161/ATVBAHA.118.312314.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Severe Acute Respiratory Syndrome
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Anticoagulants
- Glenzocimab
Other Study ID Numbers
- ACT-CS-006
- 2020-002733-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on glenzocimab
-
Acticor BiotechActive, not recruitingAcute Ischemic StrokeUnited States, Germany
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingStroke, Ischemic | Stroke, Acute
-
Acticor BiotechCompleted